— Know what they know.
Not Investment Advice

PEPG NASDAQ

PepGen Inc.
1W: -6.3% 1M: +2.8% 3M: +97.3% YTD: -58.4% 1Y: +112.9% 3Y: -50.6%
$2.98
-0.04 (-1.32%)
 
Weekly Expected Move ±8.0%
$3 $3 $3 $3 $3
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 47 · $206.1M mcap · 36M float · 2.48% daily turnover · Short 43% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$206.1M
52W Range1.31-7.8
Volume682,484
Avg Volume893,997
Beta1.97
Dividend
Analyst Ratings
5 Buy 0 Hold 1 Sell
Consensus Buy
Company Info
CEOJames McArthur
Employees57
SectorHealthcare
IndustryBiotechnology
IPO Date2022-05-06
Websitepepgen.com
321 Harrison Avenue
Boston, MA 02118
US
781-797-0979
About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
Wyman Lisa A-Award 34,000 $1.79 2026-06-18
Resnick Joshua A-Award 34,000 $1.79 2026-06-18
Mayer Howard A-Award 34,000 $1.79 2026-06-18
Finer Mitchell H. A-Award 34,000 $1.79 2026-06-18
Dable Habib J A-Award 34,000 $1.79 2026-06-18

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms